+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hypoglycemic Drugs Market, by Drug Class, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022-2030

  • PDF Icon

    Report

  • 175 Pages
  • September 2022
  • Region: Global
  • Coherent Market Insights Pvt Ltd.
  • ID: 5684949
Hypoglycemia is a condition in which blood sugar (glucose) level is lower than the standard range. Glucose is the main energy soiurce for the body. Hypoglycemia is often related to diabetes treatment. Hypoglycemia occurs when the level of glucose present in the blood falls below a set point, i.e., below 4 mmol/L (72mg/dL). The symptoms associated with Hypogyclemia are, sweating, fatigue, feeling dizzy, feeling weak, blurred vision, and others. Hypoglycemia is detected by measuring blood sugar levels with a glucose meter. Any blood glucose level below 4.0 mmol/L indicates that the individual has hypoglycemia.

Market Dynamics

Increasing prevalence of diabetes is expected to drive growth of the global hypoglycemic drugs market. For instance, according to an article published by American Diabetes Association on 28 July 2022, in 2019, 37.3 million Americans, or 11.3% of the population, had diabetes. Nearly 1.9 million Americans had type 1 diabetes, including about 244,000 children and adolescents. 1.4 million Americans are diagnosed with diabetes every year.according to same soruce, In 2014-2015, the annual incidence of diagnosed diabetes in youth was estimated at 18,200 with type 1 diabetes and 5,800 with type 2 diabetes.

Increasing number of drug approvals from regulatory bodies is expected to drive growth of the global hypoglycemic drugs market. For instance, in December 2020, Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid.

Key features of the study:

  • This report provides an in-depth analysis of the global hypoglycemic drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global hypoglycemic drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
  • Key companies covered as a part of this study include Eli Lilly & Company, Boehringer Ingelheim GmbH, Vistin Pharma AS, Janssen Pharmaceuticals NV, Sanofi, Astellas Pharma Inc., AstraZeneca plc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Teva Pharmaceuticals Pvt Ltd., and Sun Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global hypoglycemic drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global hypoglycemic drugs market

Detailed Segmentation:

Global Hypoglycemic Drugs Market, By Drug Class:

  • Sulphonylureas
  • Biguanides
  • Alpha-glucosidase inhibitors
  • Thiazolidinediones (Glitazones)
  • Dipeptidyl peptidase-4 (DPP-4) inhibitors
  • Glucagon

Global Hypoglycemic Drugs Market, By Route of Administration:

  • Oral
  • Injectable
  • Nasal

Global Hypoglycemic Drugs Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Hypoglycemic Drugs Market, By Region:

  • North America

By Country:

  • U.S.
  • Canada
  • Latin America

By Country:

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe

By Country:

  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific

By Country:

  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • Middle East

By Country:

  • GCC
  • Israel
  • Rest of Middle East
  • Africa

By Country/Region:

  • South Africa
  • Central Africa
  • North Africa

Company Profiles

  • Eli Lilly & Company*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Boehringer Ingelheim GmbH
  • Vistin Pharma AS
  • Janssen Pharmaceuticals NV
  • Sanofi
  • Astellas Pharma Inc.
  • AstraZeneca plc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Teva Pharmaceuticals Pvt Ltd.
  • Sun Pharmaceutical Industries Ltd.
Frequently Asked Questions about the Hypoglycemic Drugs Market

What is the estimated value of the Hypoglycemic Drugs Market?

The Hypoglycemic Drugs Market was estimated to be valued at $660 Million in 2022.

What is the growth rate of the Hypoglycemic Drugs Market?

The growth rate of the Hypoglycemic Drugs Market is 9.2%, with an estimated value of $1420 Million by 2030.

What is the forecasted size of the Hypoglycemic Drugs Market?

The Hypoglycemic Drugs Market is estimated to be worth $1420 Million by 2030.

Who are the key companies in the Hypoglycemic Drugs Market?

Key companies in the Hypoglycemic Drugs Market include Eli Lilly & Company, Boehringer Ingelheim GmbH, Vistin Pharma AS, Janssen Pharmaceuticals NV, Sanofi, Astellas Pharma Inc., AstraZeneca plc., Merck & Co., Inc. and Novo Nordisk A/S.

Table of Contents

1. Research Objectives and Assumptions
  • Research Objectives
  • Assumptions
  • Abbreviations
2. Market Overview
  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
  • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
  • List of Distributors
  • Key Developments
  • PEST Analysis
  • Regulatory Scenario
  • New Product Launch/ Approval
  • Acquisition and Partnership Scenario
  • Market Trends
4. Global Hypoglycemic Drugs Market - Impact of Coronavirus (Covid-19) Pandemic
  • Economic Impact
  • COVID-19 Epidemiology
  • Supply and Demand Analysis
5. Global Hypoglycemic Drugs Market, By Drug Class, 2017-2030 (US$ Million)
  • Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
  • Sulphonylureas
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Biguanides
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Alpha-glucosidase inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Thiazolidinediones
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Dipeptidyl Peptidase-4 (DPP-4) inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Glucagon
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
6. Global Hypoglycemic Drugs Market, By Route of Administration, 2017-2030 (US$ Million)
  • Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
  • Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Nasal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
7. Global Hypoglycemic Drugs Market, By Distribution Channel, 2017-2030 (US$ Million)
  • Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
  • Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
8. Global Hypoglycemic Drugs Market, By Region, 2017 - 2028 (US$ Million)
  • Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017 - 2030
  • Regional Trends
  • North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • U.S.
  • Canada
  • Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country/ Region, 2017 - 2030 (US$ Mn)
  • South Africa
  • Central Africa
  • North Africa
9. Competitive Landscape
  • Company Profiles
  • Eli Lilly & Company
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Boehringer Ingelheim GmbH
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Vistin Pharma AS
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Janssen Pharmaceuticals NV
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Sanofi
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Astellas Pharma Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • AstraZeneca plc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Merck & Co., Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Novartis AG
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Novo Nordisk A/S
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Teva Pharmaceutical Pvt. Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Analyst Views
10. Section
  • References
  • Research Methodology
  • About Us and Sales Contact

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Eli Lilly & Company
  • Boehringer Ingelheim GmbH
  • Vistin Pharma AS
  • Janssen Pharmaceuticals NV
  • Sanofi
  • Astellas Pharma Inc.
  • AstraZeneca plc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Teva Pharmaceuticals Pvt Ltd.
  • Sun Pharmaceutical Industries Ltd.